For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

Planned EDC/Rave Upgrade

Starting Sunday, March 29th, 2020 beginning at 8:00 AM EDT, and ending on Sunday, March 29th, 2020 beginning at 12:30 AM EDT. During this time there will be no access to the EDC/Rave system. Please share this notification to the personnel who will be affected by this within your organization. Maintenance Start: Sunday, March 29th, 2020 at 8:00 AM EDT. Maintenance End: Sunday, March 29th, 2020 at 12:30 AM EDT.
We are sorry for any inconvenience this may cause.

PR17 (ENZAMET) featured in ASCO's Clinical Cancer Advances 2020

PR17 (ENZAMET) featured in ASCO's Clinical Cancer Advances 2020

ENZAMET | CCTG PR17 (NCT02446405) study has been highlighted by the American Society of Clinical Oncology (ASCO) 2020 annual report as a major advance in cancer treatment. The results were first presented at ASCO 2019, the trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer.

More >>
 
An interview with Senior Investigator Annette Hay

An interview with Senior Investigator Annette Hay

Prof Annette Hay speaks to ecancer at the ASH 2019 meeting in Orlando about accrual barriers and detection of early toxicity signal in older, less-fit patients treated with azacitidine and nivolumab for newly diagnosed acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Prof Hay says that AML and MDS are typically diseases of older people, yet these patients are poorly represented in clinical trials.

More >>
 
Complementary Medications and outcomes in CCTG trials.

Palliative and supportive care presentation at ESMO 2019

Approximately a fifth of patients participating in phase III breast, lung, or colorectal cancer clinical trials conducted by CCTG also used complementary medicines.

More >>
 

Cell Therapy’s Promise for Canadians Must Include Access

An emerging form of immunotherapy, called adoptive cell transfer, has the potential to transform the way in which cancers are treated.

More >>
 

Planned trials

ALC5

Novel Therapeutics vs Azacitidine in Patients with AML or High Risk Myelodysplastic Syndrome, Aged 60 or Older (LEAP, Intergroup Less Intense AML Platform Trial)

More >>

BRC8

MRI Surveillance with or without Prophylactic Cranial Irradiation in SCLC

More >>

CEC7

Post-Surgical (SRS) Compared with (FSRS) for Resected Metastatic Brain Disease

More >>

CRC9

Circulating tumOr DNA as a Predictive BiomarRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)

More >>

GCC1

Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumours

HDC1

Nivolumab or Brentuximab Vedotin plus AVD in Pts (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

More >>

OV26

Maintenance Therapy with Olaparib and Cediranib or Olaparib Alone in Relapsed Platinum-sensitive Ovarian Cancer Following a Response to Platinum-Based Chemotherapy

More >>

PR22

Darolutamide Augments Standard Therapy for Localized High-Risk Prostate Cancer (DASL-HiCaP)

More >>

Recently activated

BR36

Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients with NSCLC

More >>

ENC1

Carboplatin & Paclitaxel with or without Pembrolizumab for Measurable Stage 3 or 4A, Stage 4B or Recurrent Endometrial Cancer

More >>

I239

CFI-400945 and Durvalumab in Patients with Advanced/Metastatic Triple Negative Breast Cancer

More >>

LY18

A Phase I Master Protocol of Novel Combination Therapy for Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma

More >>

MAC25

Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2 Positive Metastatic Breast Cancer

More >>

SC26

Emotion and Syptom-focused Engagement (EASE): Trial for Individuals with Acute Leukemia

More >>
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 
TAILORx / MAC.12 breast cancer trial showed no benefit from chemotherapy for 70% of women with the most common form of breast cancer.

TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancer

Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.

More >>
 

Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.

More >>
 
Award recipients

Canadian Cancer Research Alliance announces award winners

Canadian Cancer Research Alliance has announced the recipients of their 2017 awards: former CCTG Director, Dr. Elizabeth Eisenhauer will recieve the Exceptional Leadership in Cancer Research award and Ms. Judy Needham will receive the Exceptional Leadership in Patient Involvement in Cancer award.

More >>
 

Publications

Optimizing whole brain radiotherapy dose and fractionation: Results from a prospective phase III trial (NCCTG N107C (Alliance)/CEC.3)

International Journal of Radiation Oncology*Biology*Physics 106: 255 - 260, 2020
Trifiletti DM;Ballman KV;Brown PD;Anderson SK;Carrero XW;Cerhan JH;Whitton AC;Greenspoon J;Parney IF;Laack NN;Ashman JB;Bahary JP;Hadjipanayis CG;Urbanic JJ;Barker FG;Farace E;Khuntia D;Giannini C;Buckner JC;Galanis E;Roberge D;

More >>

Unusual Carfilzomib Toxicity: Three Cases of Drug-induced Thrombotic Microangiopathy (TMA) after Treatment with High-dose weekly Carfilzomib, Cyclophosphamide, and Dexamethasone (wCCD)

Clinical Lymphoma Myeloma and Leukemia 19: e272 - e273, 2019
Monteith B;Venner C;Reece D;Kew A;Lalancette M;Garland J;Shepherd L;McDonald G;Gul E;Pater J;Hay A;

More >>

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

N Engl J Med 381: 121 - 131, 2019
Davis ID;Martin AJ;Stockler MR;Begbie S;Chi KN;Chowdhury S;Coskinas X;Frydenberg M;Hague WE;Horvath LG;Joshua AM;Lawrence NJ;Marx G;McCaffrey J;McDermott R;McJannett M;North SA;Parnis F;Parulekar W;Pook DW;Reaume MN;Sandhu SK;Tan A;Tan TH;Thomson A;Tu E;Vera-Badillo F;Williams SG;Yip S;Zhang AY;Zielinski RR;Sweeney CJ;

More >>

Complementary medicine (CM) use in phase III clinical trials (P3T) conducted by the Canadian Cancer Trials Group (CCTG)

Ann Oncol 30, 2019
Wells JC;Sidhu A;Ding K;Heng DYC;Shepherd F;Ellis PM;Bradbury PA;Jonker DJ;Moore M;Siu LL;Gelmon KA;Karapetis C;Shapiro J;Nott L;O'Callaghan CJ;Parulekar WR;Seymour LK;Smoragiewicz M;Monzon JG;

More >>

LBA18Clinical outcomes by chemotherapy regimen in patients with RS 26-100 in TAILORx

Ann Oncol 30, 2019
Sparano J;Gray RJ;Makower D;Albain K;Saphner TJ;Badve S;Wagner L;Mihalcioiu C;Desbiens C;Hayes DF;Dees EC;Geyer C;Olson J;Wood WC;Lively T;Paik S;Ellis M;Abrams JS;Sledge GW;

More >>

Canadian cancer trials group trial IND.231: A phase 1 trial evaluating CX-5461, a novel first-in-class G-quadruplex stabilizer in patients with advanced solid tumors enriched for DNA-repair deficiencies

San Antonio Breast Cancer Symposium , 2019
Hilton J;Gelmon K;Cescon D;Tinker A;Jonker D;Goodwin R;Laurie S;Hansen A;Aparicio S;Soong J;Hagerman L;Lui H;Bedard P;Pritchard K;Tu D;Seymour L;

More >>

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205

Clinical Genitourinary Cancer 17: 201 - 208, 2019
Hotte SJ;Chi KN;Joshua AM;Tu D;Macfarlane RJ;Gregg RW;Ruether JD;Basappa NS;Finch D;Salim M;Winquist EW;Torri V;North S;Kollmannsberger C;Ellard SL;Eigl BJ;Tinker A;Allan AL;Beja K;Annala M;Powers J;Wyatt AW;Seymour L;

More >>